tradingkey.logo
tradingkey.logo
Search

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

ReutersJun 17, 2025 10:48 AM
facebooktwitterlinkedin

- Eli Lilly LLY.N will acquire Verve Therapeutics VERV.O for up to $1.3 billion, the companies said on Tuesday.

Verve is developing therapies targeting genes that regulate cholesterol in the liver.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI